19 February 2024
Physiomics plc
("Physiomics" or the "Company")
Contract Award
Physiomics plc (AIM: PYC), a leading
mathematical modelling and data science company supporting the
development of new therapeutics and personalised medicine
solutions, is pleased to announce that it has been chosen by The
University of Sheffield (the "University") to support a grant
funded project focused on an insect (Fruit fly) model of cancer
treatment. The value of this work to Physiomics will be £45k
and will commence in the second half of this calendar year.
The work is in support of one of seven cancer-focused projects
recently announced by the University (https://www.sheffield.ac.uk/news/future-cancer-research-yorkshire-receives-ps89-million-funding-boost),
all of which will be funded by Yorkshire Cancer
Research.
This work follows on from a pilot project with
the University, funded by the UK Research and Innovation (UKRI)
Higher Education Innovation Funding (HEIF) scheme (announced 31 May
2023), and Physiomics will once again be working with principal
investigator Dr Kyra Campbell, who has led a significant programme
of research in this field since December 2021. The project is
focused on the development of an insect model of cancer that could
be used to screen new drugs prior to pre-clinical testing in more
traditional models of cancer and has a particular focus on the
prediction of metastasis. This new approach could provide
important insights into the development of novel cancer therapies
as well as potentially reduce the number of pre-clinical animals
involved in the drug development process. Physiomics' role
will be to create mathematical models based on experimental data
generated by Dr Campbell and her team and explore the relationship
between the effect of drugs in these models, established models and
humans. Physiomics will also provide advice and guidance on
the possible commercialisation of the technology.
Dr Peter
Sargent, CEO of Physiomics,
commented:
"We are
delighted to have been selected once again by The University of
Sheffield to support a highly innovative research program with our
analytical and modelling capabilities. We look forward to
working with Dr Campbell and her colleagues and believe that both
our analytical capabilities, as well as our contacts and experience
within the pharmaceutical industry, could add real value to the
initiative."
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines cutting edge
PKPD and QSP modelling and data science techniques, along with deep
biology expertise, to help biotech and pharma companies streamline
their drug development journeys.
Our approach is to derive insight
from all relevant data in order to de-risk decision making and
optimise design research across discovery, pre-clinical and
clinical studies.
Through use of bespoke models and
our proprietary Virtual Tumour technology, the Physiomics team has
informed the development of over 100 commercial projects, over 50
targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle
Therapeutics, Numab Therapeutics & CRUK.